FHTX
Foghorn Therapeutics Inc
NASDAQ: FHTX · HEALTHCARE · BIOTECHNOLOGY
$4.75
-0.21% today
Updated 2026-04-30
Market cap
$311.70M
P/E ratio
—
P/S ratio
10.08x
EPS (TTM)
$-1.18
Dividend yield
—
52W range
$3 – $7
Volume
0.2M
Foghorn Therapeutics Inc (FHTX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-22.65M | $-46.34M | $-31.29M | $-50.25M | $193.61M | $-118.11M | $-100.41M | $-86.10M |
| Capital expenditures | $1.54M | $968000.00 | $16.18M | $3.31M | $1.21M | $1.22M | $906000.00 | $50000.00 |
| Depreciation | — | — | — | — | — | — | — | — |
| Stock-based comp | $732000.00 | $1.69M | $2.96M | $8.38M | $14.34M | $16.19M | $11.89M | $10.40M |
| Free cash flow | $-24.19M | $-47.30M | $-47.47M | $-53.56M | $192.40M | $-119.33M | $-101.31M | $-86.15M |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $77.27M | $8.34M | $-48.95M | — | — | — |